Myrelez (Lanreotide Acetate)

Lanreotide Acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a subcutaneous injection for subcutaneous use. It is indicated for adult patients who require long‑term suppression of excess growth hormone and related hormonal activity, and it is employed to control hormone‑secreting tumors such as acromegaly and gastroenteropancreatic neuroendocrine tumors.

GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide with adherence to stringent quality standards, regulatory approvals and reliable cold‑chain logistics where required.

Myrelez (lanreotide acetate) is a somatostatin analog that targets hormone‑secreting neuroendocrine tumors and related endocrine disorders. - Acromegaly: Provides sustained suppression of growth hormone and insulin‑like growth factor‑1, leading to reduction of soft‑tissue swelling, joint pain and cardiovascular risk. - Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs): Limits tumor proliferation and decreases secretion of vasoactive peptides, helping to control flushing, diarrhea and disease progression.

Lanreotide acetate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain: Mild discomfort or erythema at the injection site. - Diarrhea: Loose stools occurring shortly after dosing. - Nausea: Transient feeling of queasiness. - Abdominal pain: Cramp‑like discomfort in the abdomen. - Headache: Mild to moderate head pain. - Hyperglycemia: Elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects: - Gallbladder disease: Biliary sludge or cholelithiasis leading to gallstone formation. - Pancreatitis: Inflammation of the pancreas presenting with severe abdominal pain. - Cardiac arrhythmias: Irregular heart rhythms requiring medical attention. - Severe allergic reactions: Anaphylaxis or angioedema.

When prescribing Myrelez, clinicians should consider several precautionary measures to ensure safe use. - Renal function: Assess kidney function before initiating therapy and monitor periodically. - Hepatic impairment: Use with caution in patients with liver disease, adjusting monitoring as needed. - Diabetes mellitus: Monitor blood glucose closely, as the drug may worsen hyperglycemia. - Gallbladder status: Evaluate for pre‑existing gallstones or biliary disease before treatment. - Pregnancy and lactation: Avoid use during pregnancy and breastfeeding unless benefits outweigh risks. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Lanreotide acetate can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: May increase lanreotide plasma concentrations, raising risk of adverse effects. - Somatostatin analogs combination: Concurrent use can lead to additive hormonal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: Lanreotide may impair glucose control, requiring dose adjustments. - Hormonal contraceptives: Potential reduction in contraceptive effectiveness. - Octreotide: Overlapping mechanisms may increase gastrointestinal side effects. - Digoxin: Possible alteration in drug levels; monitor therapeutic range.